The next sections will delineate current oncogenic biomarkers in lung cancer, reviewing the background, clinical features, detection methods, most common alterations and FDA-approved therapies.
Figure 1. Oncogenic mutations in Non-Small Cell Lung Cancer (NSCLC) by histology.
Adapted from: Chan BA, et al. Transl Lung Cancer Res. 2015;doi:10.3978/j.issn.2218-6751.2014.05.01.
Thank you for participating in this module. Click below to download the certificate.